Menopausal Hormone Therapy and Breast Cancer Outcomes
Author Information
Author(s): Lena U. Rosenberg, Fredrik Granath, Paul W. Dickman, Kristjana Einarsdóttir, Sara Wedrén, Ingemar Persson, Per Hall
Primary Institution: Karolinska Institutet
Hypothesis
How does menopausal hormone therapy (MHT) influence breast cancer characteristics and survival?
Conclusion
Current use of menopausal hormone therapy, especially long-term, is associated with favorable tumor characteristics and improved survival in breast cancer patients.
Supporting Evidence
- Current MHT users had lower grade tumors compared to never users.
- Long-term MHT use was associated with improved breast cancer-specific survival.
- Recent mammography did not explain the survival advantage among MHT users.
- Women using MHT had a lower risk of dying from breast cancer compared to non-users.
Takeaway
Women who used hormone therapy before being diagnosed with breast cancer had better tumor characteristics and lived longer than those who didn't use it.
Methodology
The study analyzed data from 2,660 postmenopausal women diagnosed with invasive breast cancer, assessing the influence of hormone therapy on tumor characteristics and survival.
Potential Biases
Nonparticipants had larger tumors and more lymph node involvement, which may skew results if their characteristics differ significantly from participants.
Limitations
The study had a high non-participation rate and missing data on some tumor characteristics, which could introduce bias.
Participant Demographics
Postmenopausal women aged 50 to 74 years diagnosed with invasive breast cancer.
Statistical Information
P-Value
0.57
Confidence Interval
0.41 to 0.79
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website